Another method to target CD19 expressing tumor cells is via blinatumomab, which is a bispecific T cell engager antibody construct which has specificity for both CD19 and CD3 antigens, with the goal of engaging the CD3-expressing cytotoxic T cells to lyse CD19 expressing tumor cells [54]. Here, CD19 is linked to neoplasm.